Trial Profile
Comparison of neurological and psychiatric events in HIV-infected patients treated with dolutegravir, raltegravir and elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2017
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Abacavir/dolutegravir/lamivudine; Dolutegravir; Raltegravir
- Indications HIV infections
- Focus Adverse reactions
- 24 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017